Clinical Trial Finder

Inclusion Criteria:

• - HLA-A*02:01-positive.

• - unresectable Stage III or Stage IV non-ocular melanoma.

• - archival tumor tissue sample or a newly obtained biopsy of a tumor lesion not previously irradiated has been provided.

• - measurable or non-measurable disease per RECIST 1.1.

• - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

• - If applicable, must agree to use highly effective contraception.

• - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol.

Exclusion Criteria:

• - Pregnant or lactating women.

• - diagnosis of ocular or metastatic uveal melanoma.

• - history of a malignant disease other than those being treated in this study.

• - ineligible to be retreated with pembrolizumab due to a treatment-related AE.

• - known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.

• - previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) - active autoimmune disease requiring immunosuppressive treatment.

• - clinically significant medical condition.

• - known psychiatric or substance abuse disorders.

• - received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication.

• - received chemotherapy or biological cancer therapy (excluding anti-PD(L)1 mAb, ipilimumab, and BRAF TKI regimen) within 14 days of first dose.

• - received cellular therapies within 90 days of first dose.

• - received systemic treatment with steroids or any other immunosuppressive drug within 2 weeks of first dose.

• - have not progressed on treatment with an anti-PD(L)1 mAb.

• - have not received prior ipilimumab.

• - a BRAF V600 mutation, who have not received a prior BRAF/MEK TKI regimen.

• - currently participating or have participated in a study of an investigational agent or using an investigational device within 30 days of the first dose.

• - known history of chronic viral infections.

• - Out of range Laboratory values.

- history of allogenic tissue/solid organ transplant

This is a Phase 2/3, multicenter, open-label study to evaluate the efficacy and safety of tebentafusp as monotherapy (Arm A) and in combination with pembrolizumab (Arm B) compared with standard of care or best supportive care (Arm C) in participants with non-ocular advanced melanoma who have progressed on a prior anti-PD(L)1 regimen, received prior ipilimumab and, if the participant has a BRAF mutation, a prior BRAF tyrosine kinase inhibitor (TKI) regimen.

Arms

Experimental: Arm A

Tebentafusp as single agent

Experimental: Arm B

Tebentafusp in combination with Pembrolizumab

Experimental: Arm C

Straight to on protocol survival follow up including investigators choice of therapy

Interventions

Drug: - Tebentafusp

soluble gp100-specific T cell receptor with anti-CD3 scFV

Drug: - Tebentafusp with Pembrolizumab

soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with Pembrolizumab

Drug: - Investigators Choice

Investigators choice of therapy